HORIZON EUROPE | CALL OPENING

December 17, 2021

From ASPHALION, we would like to inform you of the opening of the call:

  • HORIZON-HLTH-2022-DISEASE-06-02-two-stage: “Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs”

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizon-hlth-2022-disease-06-02-two-stage

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 3 “Tackling diseases and reducing disease burden”.

Immunotherapy is defined as a treatment able to stimulate or restore the ability of the immune (defence) system to fight infection, disease or disorder. It has proved to be a valuable medical treatment notably when preventive interventions are not available. Passive and active immunotherapies (such as antibody-based, RNA-based and cell-based therapies, respectively) are covered by this topic, which is aiming at the pre-clinical to first-in human development of next generation immunotherapies for unmet needs.

ASPHALION, as SME company, is actively involved in more than 15 EU granted projects as regulatory expert partners.

Whether you are planning to apply and you would like to add a regulatory partner to the project, or if you are interested in knowing more about ASPHALION and our European granted projects expertise, do not hesitate to contact us at: [email protected]

 

 

 

Search News & Events

  • Filter by category

Share

Related news and events

HORIZON EUROPE | NABIHEAL progress meeting

Two years into the NABIHEAL project, Asphalion experts Marta Rayo Lunar and Sergio Veiga attended the consortium meeting in Zagreb, hosted by IMI, to review

HORIZON EUROPE PROJECT | KeratOPrinter Kick-Off Meeting

Corneal blindness affects over 11.7 million people worldwide, yet only 1 in 70 patients receive a corneal transplant due to a severe donor shortage. The KeratOPrinter project aims to address this gap by developing a groundbreaking 4D bioprinting suite capable of producing fully functional, biocompatible human corneas. Combining expertise from world-class partners, the project focuses on scalable cell sources, advanced bioinks, high-precision bioprinting, clinical handling solutions, regulatory compliance, and a strong collaborative network. By 2035, KeratOPrinter seeks to revolutionize corneal transplantation and restore vision for millions.

ARDAT PROJECT

A new year, new classes, and a deep dive into advanced therapies, including discussions on the ARDAT project, as part of the University of Sheffield’s

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting